Evidence map›Paper›PMID 40881422›Full record

ArticleJACS Au2025

DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement.

Disha Kashyap, Shozeb Haider, Thomas A Milne, Michael J Booth

Erratum issuedAbstract read
In one paragraph

Article in JACS Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Disha KashyapDepartment of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.
Shozeb HaiderUCL School of Pharmacy, University College London, London WC1N 1AX, U.K.ORCID https://orcid.org/0000-0003-2650-2925
Thomas A MilneMRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, U.K.
Michael J BoothDepartment of Chemistry, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.ORCID https://orcid.org/0000-0002-4224-798X

Funding

Wellcome Trust
6 · The paper itself

Abstract

Targeted protein degradation is a powerful therapeutic approach: expanding the druggable proteome, providing enhanced selectivity, and having the ability to overcome conventional resistance mechanisms. A major class of such molecules is proteolysis-targeting chimeras (PROTACs). PROTACs are catalytic heterobifunctional small molecules that simultaneously bind a protein of interest (POI) and an E3 ligase. And thus, PROTACs induce a proximity-dependent ubiquitination of the POI and its subsequent degradation by the ubiquitin-proteasome system. While PROTACs have successfully transitioned from academia to industry, increasing awareness of off-target effects and related toxicities highlights the urgent need for precise control mechanisms over activity. Achieving this level of control, however, remains challenging, with traditional chemistries. DNA nanotechnology, with its unparalleled programmability and structural versatility, presents a powerful tool for achieving such control. Here, we report the design and characterization of oligonucleotide-linked PROTACs (OligoPROTACs). These constructs comprise PROTAC warheads covalently linked to separate complementary DNA strands, brought together in space via DNA hybridization. OligoPROTACs are able to degrade the POI in a distance-dependent manner. Furthermore, we demonstrate the first instance of a dynamic off-switch mechanism for PROTAC activity, enabled by toehold-mediated strand displacement using a third DNA strand. This work highlights the potential of DNA nanotechnology combined with the clinical emergence of nucleic acid therapeutics to enhance the safety and functionality of PROTAC systems, paving the way for more refined and translatable therapeutic strategies.

Indexed as

BRD4 degradationDNA nanotechnologyJQ1oligonucleotide-linked PROTACsPROTACstoehold-mediated strand displacementVH032VHL E3 ligase

Identifiers

PMID40881422
PMCPMC12381747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.